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Postural modification to the standard Valsalva manoeuvre 
for emergency treatment of supraventricular tachycardias 
(REVERT): a randomised controlled trial
Andrew Appelboam, Adam Reuben, Clifford Mann, James Gagg, Paul Ewings, Andrew Barton, Trudie Lobban, Mark Dayer, Jane Vickery, 
Jonathan Benger, on behalf of the REVERT trial collaborators
Summary
Background The Valsalva manoeuvre is an internationally recommended treatment for supraventricular tachycardia, 
but cardioversion is rare in practice (5–20%), necessitating the use of other treatments including adenosine, which 
patients often find unpleasant. We assessed whether a postural modification to the Valsalva manoeuvre could 
improve its effectiveness.
Methods We did a randomised controlled, parallel-group trial at emergency departments in England. We randomly 
allocated adults presenting with supraventricular tachycardia (excluding atrial fibrillation and flutter) in a 1:1 ratio to 
undergo a modified Valsalva manoeuvre (done semi-recumbent with supine repositioning and passive leg raise 
immediately after the Valsalva strain), or a standard semi-recumbent Valsalva manoeuvre. A 40 mm Hg pressure, 15 s 
standardised strain was used in both groups. Randomisation, stratified by centre, was done centrally and independently, 
with allocation with serially numbered, opaque, sealed, tamper-evident envelopes. Patients and treating clinicians 
were not masked to allocation. The primary outcome was return to sinus rhythm at 1 min after intervention, 
determined by the treating clinician and electrocardiogram and confirmed by an investigator masked to treatment 
allocation. This study is registered with Current Controlled Trials (ISRCTN67937027).
Findings We enrolled 433 participants between Jan 11, 2013, and Dec 29, 2014. Excluding second attendance by 
five participants, 214 participants in each group were included in the intention-to-treat analysis. 37 (17%) of 
214 participants assigned to standard Valsalva manoeuvre achieved sinus rhythm compared with 93 (43%) of 214 in 
the modified Valsalva manoeuvre group (adjusted odds ratio 3·7 (95% CI 2·3–5·8; p<0·0001). We recorded no serious 
adverse events.
Interpretation In patients with supraventricular tachycardia, a modified Valsalva manoeuvre with leg elevation and 
supine positioning at the end of the strain should be considered as a routine first treatment, and can be taught 
to patients.
Funding National Institute for Health Research.
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Introduction
The Valsalva manoeuvre is a safe and internationally 
recommended first-line emergency treatment for 
supraventricular tachycardia, a common and ubiquitous 
group of cardiac arrhythmias.1–6 However, cardioversion 
is rarely successful in clinical practice (5–20%),7–9 and 
patients who remain in supraventricular tachycardia are 
usually treated with intravenous adenosine. Adenosine 
causes transient asystole and is associated with 
substantial side-effects: many patients report a sense of 
impending doom or feel that they are about to die and 
find this very unpleasant and frightening.10,11
Modifications to increase relaxation phase venous 
return and vagal stimulation, including supine 
positioning with leg elevation immediately after the 
Valsalva strain (the modified Valsalva manoeuvre), might 
improve the Valsalva manoeuvre’s effectiveness,12–18 but 
have not been assessed in controlled trials with patients 
presenting with acute supraventricular tachycardia.19 An 
improvement in the success rate of the Valsalva 
manoeuvre with a simple, safe, and cost-free modification 
to patient positioning during the manoeuvre would be an 
important finding, with benefits for patients and 
health-care providers worldwide, including regions with 
few health-care resources.18
We did a randomised controlled trial (REVERT) to 
assess whether a modified Valsalva manoeuvre is more 
effective than a standard Valsalva manoeuvre at restoring 
sinus rhythm in patients presenting to hospital with 
supraventricular tachycardia.
Methods
Study design and participants
We did this pragmatic, randomised, multicentre parallel 
group trial in ten emergency departments (two teaching 
hospitals, eight district general hospitals) in southwest 
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England between Jan 1, 2013, and April 30, 2015. The 
study was run according to a previously described 
design,20 through the Peninsula Clinical Trials Unit at 
Plymouth University, overseen by an independently 
chaired trial steering committee.
Patients with suspected supraventricular tachycardia 
(at emergency department triage or initial assessment) 
were screened for participation, including routine 
12-lead electrocardiogram (ECG), before any emergency 
arrhythmia treatment. We included patients aged older 
than 18 years presenting to the emergency department 
with supraventricular tachycardia (regular, narrow 
complex tachycardia with QRS duration <0·12 s on 
ECG). We excluded unstable patients with systolic 
blood pressure less than 90 mm Hg or an indication 
for immediate cardioversion and those in atrial 
fibrillation or flutter. Other exclusion criteria were 
suspected atrial flutter requiring a trial of adenosine, 
the presence of any contraindication to Valsalva 
manoeuvre (aortic stenosis, recent myocardial 
infarction, glaucoma, retinopathy), inability to per-
forming a Valsalva manoeuvre, to lie flat, or have 
legs lifted (or any reason identified by the patient as to 
why this manoeuvre would cause discomfort or pain), 
third trimester pregnancy, or previous inclusion in 
this study.
The study was approved by the South West—Exeter 
Research Ethics Committee, and done in accordance 
with Good Clinical Practice principles. All participants 
provided written informed consent.
Randomisation and masking
Participants were randomly assigned (1:1) to a standard 
Valsalva manoeuvre (control) or modified Valsalva 
manoeuvre (intervention) as their first treatment with 
permuted blocks of size two, four, and six, stratified by 
centre. Allocations were prepared by an independent 
statistician and placed in serially numbered, opaque, 
sealed, tamper-evident envelopes by the clinical 
trials unit.
Treatment was determined by selecting the next 
randomisation envelope in sequence and was checked 
against a randomisation log. The recruiting doctor or 
nurse had to sign and date the envelope across the seal to 
confirm that the next available and lowest numbered 
envelope of the batch had been taken and that it had not 
been opened previously. Correct and sequential use of 
envelopes as described in the protocol was strictly audited 
by the site research team and clinical trials unit. This 
process enabled effective randomisation and immediate 
availability of trial paperwork, without the need for 
telephone or computer use, and was specifically chosen 
to aid successful consecutive recruitment in the 
emergency department.
Treating clinicians could not practically be masked 
to the allocation. Trial paperwork and explanations 
disguised from participants which was the study 
intervention and which was the control by use of 
descriptive terms for each Valsalva manoeuvre. All 
analyses were done by investigators masked to treatment 
allocation.
Research in context
Evidence before this study
We searched MEDLINE, Embase, and CINAHL databases for 
“Valsalva manoeuvre AND supraventricular tachycardia OR 
re-entrant tachycardia” using MeSH terms and appropriate 
variations in 2009, before our study began. We excluded 
studies of children and those that did not describe the 
Valsalva manoeuvre. 269 citations were reviewed and 
six studies were relevant to our research question. We also 
searched the Cochrane and Bandolier databases using the 
terms “Valsalva” and “supraventricular tachycardia”, and 
found no relevant articles. A repeat of the search on 
April 15, 2015 identified a Cochrane Review (updated from 
2013), which included three studies, all of which we had 
reviewed in 2009.
Of the six studies reviewed, only two directly assessed the 
effect of posture on Valsalva manoeuvre effectiveness. 
One compared supine and sitting Valsalva manoeuvre for 
induced supraventricular tachycardia in an electrophysiology 
laboratory and the other was an uncontrolled trial of 
Trendelenberg Valsalva manoeuvre for acute supraventricular 
tachycardia in an emergency department. No randomised 
controlled trials compared posture for the management of 
patients with acute supraventricular tachycardia presenting 
to hospital.
Added value of this study
This study is the first randomised controlled trial to assess the 
effect of posture modification to the Valsalva manoeuvre in 
patients presenting with acute supraventricular tachycardia. 
A standard strain was used to ensure that the Valsalva 
manoeuvre, other than the change in posture, was the same for 
both groups. This study was pragmatic, done in a clinical setting 
to which patients often present, and used usual treating staff. 
The proportion of cardioversions should therefore occur in 
normal practice if the modified technique is adopted, and serves 
as a baseline against which future studies can be compared.
Implications of all the available evidence
In patients presenting with stable supraventricular tachycardia, 
a 15 s, 40 mm Hg Valsalva strain in the semi-recumbent 
position should be followed immediately by supine 
repositioning and passive leg elevation. It should be repeated 
once if unsuccessful. Consideration should be given to enabling 
patients to do this themselves, and for making this a standard 
initial treatment.
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Procedures
For both groups, the Valsalva manoeuvre strain was 
standardised to a pressure of 40 mm Hg sustained for 
15 s by forced expiration measured by aneroid manometer 
with the target pressure marked and visible to the 
participant and treating team.19 Standardised verbal 
instructions were used to help participants to achieve 
target pressure and strain duration.
The control manoeuvre was termed the “stay sitting 
Valsalva” to reduce bias. Participants, positioned 
semi-recumbent (at 45°) on a trolley, were directed to 
perform the standardised strain and remained in the 
same position for 60 s before reassessment of cardiac 
rhythm, initially by 3-lead ECG. A training video was 
given to all participating centres.
The modified Valsalva manoeuvre (intervention) was 
termed “lying down with leg lift Valsalva” (video). 
Participants performed the standardised strain in the 
same semi-recumbent position but immediately at the 
end of the strain, were laid flat and had their legs raised 
by a member of staff to 45° for 15 s. Participants were 
then returned to the semi-recumbent position for a 
further 45 s before re-assessment of cardiac rhythm, 
initially by 3-lead ECG.
If sinus rhythm was not restored, participants were 
invited to undertake one further attempt at the allocated 
Valsalva manoeuvre. A 12-lead ECG was recorded if 
return to sinus rhythm was achieved at 1 min after 
Valsalva manoeuvre, and 1 min after the second 
manoeuvre even if unsuccessful.
Treating clinicians or the research nurses recorded 
whether the allocated Valsalva manoeuvre was performed, 
the peak pressure and the total duration of strain 
achieved, whether sinus rhythm was restored, and any 
adverse events.
Subsequent management was entirely at the discretion 
of the treating clinical team according to standard 
guidelines. At discharge, participants were given written 
instructions on how to perform both types of Valsalva 
manoeuvre themselves using a 10 mL syringe21 and 
provided with the website address of the Arrhythmia 
Alliance, a patient support charity.
Participants were followed up until discharge from 
the emergency department. Participant demographics, 
details of past medical history, subsequent emergency 
department treatment, and time spent in the emergency 
department were also recorded. We retrospectively 
screened all emergency department attendances 
during the trial period to get local feedback of missed, but 
potentially eligible patients, and to more fully describe the 
population from which our participants were recruited.
Outcomes
The primary outcome was the presence of sinus rhythm 
as recorded by the treating clinician 1 min after Valsalva 
manoeuvre and confirmed by ECG in the intention-to-treat 
population. All trial ECGs were retrospectively assessed 
by an independent cardiologist, masked to treatment 
allocation. Disagreement with the treating clinician’s 
ECG interpretation was arbitrated by an independent 
electrophysiologist masked to treatment allocation. 
Primary outcome data were corroborated by an 
independently chaired endpoint committee when 
necessary. Every attempt was made to retrieve missing 
data. In cases where the post-Valsalva manoeuvre ECG 
was missing, primary outcome was confirmed by 
endpoint committee. Such cases were reviewed in detail 
with all available evidence to confirm the primary 
outcome. For the purpose of the intention-to-treat analysis 
only, spontaneous cardioversion that occurred after 
randomisation but before intervention, was considered a 
treatment success, but all such cases were also reviewed 
by the endpoint committee.
Secondary outcomes were the use of adenosine, the 
use of any emergency treatment for supraventricular 
tachycardia (including adenosine), the need and reason 
for admission to hospital, the length of time participants 
spent in the emergency department, and adverse events. 
We also compared the adequacy of the Valsalva 
manoeuvre strain. To enable a per-protocol analysis and 
description of the cohort, participants’ presenting 
arrhythmias were also retrospectively classified by the 
clinicians’ final diagnoses and expert ECG reports with 
recourse to the arbiter when there was disagreement.
Statistical analysis
To calculate the required sample size, we estimated 
that the standard Valsalva manoeuvre would cause 
cardioversion in 15% of patients with supraventricular 
tachycardia on the basis of local audit data and previous 
studies.8,9,14 We powered our study to be able to detect at 
least a 12% absolute improvement with the modified 
Valsalva manoeuvre, using the available evidence and 
the minimum improvement we thought would effect a 
change in practice. We estimated that this difference 
would require 186 patients per group (assuming a 
two-tailed test of statistical significance with an α of 0·05 
and power of 0·8), and a 22 month recruitment period 
across ten centres.
We expected that some patients would spontaneously 
revert to sinus rhythm between randomisation and 
intervention. We closely monitored rates of spontaneous 
cardioversion, recruitment, and emergency department 
final diagnoses. We recruited ahead of target but noted 
that 5% of participants had spontaneous cardioversion 
after randomisation and before intervention, and a 
higher than expected recruitment of participants with 
non-eligible tachycardia (mainly atrial flutter). It was 
therefore decided, with agreement of the steering 
committee, to continue recruiting until the end of the 
planned recruitment period to maximise the number of 
participants with eligible supraventricular tachycardia, to 
meet our initial sample size assumptions and increase 
trial precision.
For the Arrhythmia Alliance see 
http://www.arrhythmiaalliance.
org.uk
See Online for video
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There was no opportunity for crossover of trial 
treatments except in the case of error, and participants 
were analysed according to intention to treat. In 
accordance with the statistical analysis plan, second 
episode data from patients recruited in error for a second 
time were excluded.
We report baseline data descriptively by group. We 
compared binary outcomes (including the primary 
outcome) using mixed effects logistic regression with 
allocation group as a fixed effect and centre as a random 
effect. We analysed time spent in the emergency 
department using Cox proportional hazards regression 
with a shared frailty model (for centre).
We also did a per-protocol analysis excluding 
participants who did not undertake at least one trial 
Valsalva manoeuvre and those with trial ineligible 
tachycardias (protocol violations). These patients were 
identified by a final emergency department diagnosis of 
ineligible tachycardia (atrial flutter, atrial fibrillation, 
sinus tachycardia, or broad complex tachycardia) or by 
agreement of expert ECG reviewer and arbiter that the 
pre-intervention ECG showed one of these excluded 
arrhythmias. 
The trial had no separate data and safety monitoring 
committee; however, adverse event data and overall 
cardioversion rates were monitored by the steering 
committee to ensure safety and non-futility. We did the 
statistical analyses with Stata (version 14.0).
The study is registered with Current Controlled Trials, 
ISRCTN67937027.
Role of the funding source
The funder of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and final responsibility 
for the decision to submit for publication.
Results
Between Jan 11, 2013, and Dec 29, 2014, 1170 patients 
attended participating sites with suspected supra-
ventricular tachycardias and of these, 711 patients were 
screened. We randomly assigned 433 participants, 216 to 
receive a standard Valsalva manoeuvre and 217 to receive 
the modified Valsalva manoeuvre (figure). 164 different 
clinicians delivered the intervention. Data for the second 
attendance from five patients who were recruited twice in 
error were omitted from the analyses, leaving 214 in each 
group. Spontaneous cardioversion after randomisation 
and before intervention occurred in nine (4%) of 
214 participants in the standard group and 12 (6%) of 
214 in the modified Valsalva manoeuvre group. 
Of the 428 participants included in the primary analysis, 
205 attempted at least one standard Valsalva manoeuvre 
and 201 at least one modified Valsalva manoeuvre 
according to allocation. 179 participants in the standard 
Valsalva manoeuvre group and 131 in the modified 
Valsalva manoeuvre group who remained 
in supraventricular tachycardias attempted a second 
manoeuvre as allocated.
There was no crossover of treatment and similar 
numbers of patients in each group achieved the defined 
study strain with 173 (84%) of 205 participants with strain 
data in the standard group and 173 (86%) of 202 in the 
modified group reaching the target pressure and duration 
of strain. One participant allocated to the modified 
Valsalva manoeuvre was identified as being in atrial 
fibrillation before any trial intervention and seven 
participants in each group withdrew before doing a 
second Valsalva manoeuvre but all consented to their data 
Figure: Trial profile
VM=Valsalva manoeuvre. ECG=electocardiogram.
1170 patients attended emergency department
with suspected supraventricular tachycardia 
711 assessed for eligibility 
433 randomly assigned  
459 not formally screened 
200 did not meet eligibility criteria 
131 had spontaneous cardioversion 
128 missed but potentially eligible 
278 not enrolled 
241 did not meet eligibility criteria 
86 spontaneous cardioversion 
46 atrial fibrillation or flutter (or suspected) 
46 previously included in study 
42 unstable condition
13 contraindicated to VM or lying flat
4 in third trimester of pregnancy 
3 younger than 18 years old
1 other 
20 eligible but not enrolled
18 emergency department too busy
2 treating physician failed to locate study 
documents or equipment 
17 declined to participate 
216 allocated to control
207 received allocated treatment 
9 did not receive allocated treatment
9 had spontaneous cardioversion 
217 allocated to intervention
204 received allocated treatment 
13 did not receive allocated treatment 
12 had spontaneous cardioversion
1 had atrial fibrillation 
3 excluded (repeat enrolment)2 excluded (repeat enrolment)
214 had data for primary outcome 
209 had data collected as per protocol 
5 had no ECG available (inferred by 
endpoint committee)
214 had data for primary outcome 
208 data collected as per protocol
5 had no ECG available (inferred by endpoint 
committee)
1 had no ECG available (inferred from 
trial data or other treatment) 
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being used. No patients were lost to follow-up and data 
for all randomised participants, excluding the second 
attendance data of five patients who had previously been 
recruited to the trial, were analysed (figure).
Baseline demographic, past medical history, and 
presenting physiological data were similar in each group 
(table 1). Potentially eligible patients who were not 
formally screened had similar demographic features to 
the recruited population (data not shown).
93 (43%) of 214 participants in the modified Valsalva 
manoeuvre group versus 37 (17%) of 214 participants in the 
standard Valsalva manoeuvre group achieved the primary 
outcome of sinus rhythm at 1 min (odds ratio [OR] 3·7, 
95% CI 2·3–5·8; p<0·0001; table 2). The absolute 
difference was 26·2%; thus, three patients needed the 
modified Valsalva manoeuvre to avoid one case of further 
treatment.
This finding was confirmed by analysis of primary 
source data with expert review of 12-lead post-intervention 
ECGs in 417 (97%) patients, and by the agreement of the 
endpoint committee in ten (2%) patients (five in each 
group). A further patient, for whom there was no 
post-intervention ECG, was identified as being in atrial 
fibrillation after enrolment and did not undergo a 
Valsalva manoeuvre. In both groups, for those who had 
sinus rhythm restored with a Valsalva manoeuvre, 
cardioversion occurred mostly at the first manoeuvre. 
However, nine patients in the standard Valsalva 
manoeuvre group and 18 in the modified Valsalva 
manoeuvre group cardioverted at the second attempt.
Use of adenosine was significantly lower in the 
modified Valsalva manoeuvre group than in the standard 
Valsalva manoeurve group (table 2). Only four patients 
had recurrence of supraventricular tachycardia requiring 
further treatment in the emergency department. All 
had initially achieved sinus rhythm with the modified 
Valsalva manoeuvre. The requirement for any emergency 
department anti-arrhythmic treatment (appendix) after 
Valsalva manoeuvre was rarer in the modified Valsalva 
manoeuvre group than the standard Valsalva manoeuvre 
group (table 2). Neither time spent in the emergency 
department nor need for admission differed significantly 
between groups (table 2).
No serious adverse events were reported. Non-serious 
adverse events were more common in the modified 
Valsalva manoeuvre group than in the standard Valsalva 
manoeuvre group, but not significantly so (table 3). ECG 
escape events, such as ventricular beats, were occasionally 
reported during successful cardioversion in the modified 
Valsalva manoeuvre group (table 3). The five 
electrocardiograph-captured events were one asystolic 
pause and four episodes of ventricular escape activity, all 
of which resolved spontaneously. All adverse events were 
transient and self-limiting, requiring no additional 
treatment.
Excluding patients with non-eligible tachycardias 
(table 4) and those who did not undergo a trial intervention 
resulted in a greater difference between the groups, with 
28 (15%) of 183 participants in the standard Valsalva 
manoeuvre group achieving sinus rhythm compared with 
81 (47%) of 173 in the modified Valsalva manoeuvre group 
(adjusted OR 4·9, 95% CI 2·9–8·0; p<0·0001).
Discussion
We have shown that a simple, cost-free, well-tolerated 
postural modification to the standard Valsalva manoeuvre 
is highly effective, returning more than 40% of patients to 
sinus rhythm compared with 17% with a standard Valsalva 
manoeuvre. This difference resulted in a substantial 
reduction in the number of patients needing other 
emergency treatments, particularly adenosine. Fewer 
patients treated with the modified Valsalva manoeuvre 
needed further emergency department treatment, 
compared with the standard Valsalva manoeuvre.
See Online for appendix
Standard VM 
(n=214)
Modified VM 
(n=214)
Men 80 (37%) 89 (42%)
Age (years) 54·5 (16·8) 55·1 (16·3)
Previous SVT (undiagnosed) 57 (27%) 63 (29%)
Previous SVT (diagnosed) 103 (48%) 97 (45%)
Previous ablation treatment 15 (7%) 19 (9%)
Ischaemic heart disease 7 (3%) 11 (5%)
Diabetes 18 (8%) 25 (12%)
Hypertension 36 (17%) 47 (22%)
Valvular heart disease 5 (2%) 1 (<1%)
Pneumonia 4 (2%) 2 (1%)
COPD 7 (3%) 2 (1%)
Systolic BP (mm Hg) 124 (22) 125 (23)
Diastolic BP (mm Hg) 82 (18) 83 (19)
Pulse (beats per minute) 179 (29) 172 (29)
O2 saturation (%) 97·9 (2·1) 98·0 (1·9)
Data are n (%) or mean (SD). VM=Valsalva manoeuvre. SVT=supraventricular 
tachycardia. COPD=chronic obstructive pulmonary disease. BP=blood pressure.
Table 1: Baseline characteristics
Standard VM 
(n=214)
Modified VM 
(n=214)
Effect size (95%CI) p value
Presence of sinus rhythm at 
1 min after VM
37 (17%) 93 (43%) 3·7 (2·3–5·8) <0·0001
Adenosine given 148 (69%) 108 (50%) 0·45 (0·30–0·68) 0·0002
Any emergency 
anti-arrhythmic treatment
171 (80%) 121 (57%) 0·33 (0·21–0·51) <0·0001
Discharged home from 
emergency department 
146 (68%) 134 (63%) 0·79 (0·51–1·21) 0·28
Any adverse event 8 (4%) 13 (6%) 1·61 (0·63–4·08) 0·32
Time in emergency 
department (h; median, IQR)
2·83 (1·95–3·62) 2·82 (1·95–3·77) 0·90 (0·75–1·10) 0·31
Effect sizes are adjusted odds ratios, except for time in emergency department, which is an adjusted hazard ratio. 
VM=Valsalva manoeuvre. 
Table 2: Primary and secondary outcomes
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We did not detect any time saving or reduced need for 
hospital admission. Most treatments for supraventricular 
tachycardia take little time and take up only a small 
proportion of the total time spent in the emergency 
department. Likewise, the need for hospital admission is 
usually determined by the presence of concurrent 
medical conditions and not for the supraventricular 
tachycardia per se, which was similar in each group.
A higher proportion of patients had cardioversion in our 
study than in most observational studies,19 but the 
proportion in the control group was similar to that on 
which we based our sample size and within the range in 
routine practice. By contrast, the proportion of patients 
who cardioverted in the modified Valsalva manoeuvre 
group was substantially higher than that reported in other 
studies of emergency supraventricular tachycardia vagal 
treatments, and greater than the 31% reported by Walker 
and Cutting with a Trendelenberg (supine with head down 
incline) Valsalva manoeuvre.14 We believe that there are 
sound physiological reasons for this difference, with the 
sequence and timing of the strain and changes to position 
all important to the success of our particular modification.
We compared a modified Valsalva manoeuvre with the 
Valsalva manoeuvre most commonly used in routine 
practice in this setting.7,14,16 Although a supine Valsalva 
manoeuvre achieves greater vagal tone in healthy patients 
or those with induced supraventricular tachycardia,17,22 
patients are routinely assessed in a semirecumbent 
position and there might be benefits from starting the 
Valsalva manoeuvre in this position (augmenting the 
initial fall in venous return on straining) before 
maximising venous return in the relaxation phase 
(Valsalva stage 3) through supine position and passive 
leg lift.
Treating clinicians could not be masked to treatment 
allocation but we used strict allocation concealment 
and standardised instructions, and disguised from 
participants which allocation was the intervention and 
which was control. Subsequent emergency department 
treatment was unlikely to be influenced by knowledge of 
trial allocation because patients would not conceivably 
have been left in supraventricular teachycardia without 
treatment or treated with adenosine when in sinus 
rhythm. Strain data confirmed the equivalence of the 
Valsalva manoeuvre strain effort in both groups.
We recruited a higher proportion of patients with non-
eligible supraventricular tachycardia (mainly atrial flutter) 
than expected, as a result of the difficulty of distinguishing 
such rhythms from re-entrant supraventricular 
tachycardia in an emergency department. Improving the 
detection and exclusion of these rhythms might further 
improve the efficacy of the modified Valsalva manoeuvre, 
as suggested by the per-protocol analysis. We did not 
assess the relative frequency of re-entrant supraventricular 
tachycardia subtypes—eg, atrioventricular nodal re-entry 
tachycardia and atrioventricular re-entry tachycardia. This 
distinction is not routinely, accurately, or reliably made 
at presentation and does not affect initial hospital 
management or preclude use of a Valsalva manoeuvre as 
first-line treatment.
Future work should assess the implementation and 
dissemination of this technique and its performance in 
routine practice. Studies comparing it with the fully 
supine Valsalva manoeuvre in both patients and healthy 
volunteers should also be considered.
An improved Valsalva manoeuvre that is successful in 
50% of cases has potential benefits for patients with 
supraventricular tachycardia worldwide. Our study was 
pragmatic and done in an environment in which these 
patients are often treated, but used a modification that 
can be done anywhere, including community and 
resource-poor settings, without specialist equipment. We 
used a manometer to ensure a consistent and 
measurable 40 mm Hg strain, but a 10 mL syringe blown 
to just move the plunger generates a similar pressure.21
We did not identify any disadvantages of using the 
modified Valsalva manoeuvre technique. As long as 
individuals can safely undertake a Valsalva strain and be 
repositioned as described, this manoeuvre can be used 
as the routine initial treatment for episodes of 
supraventricular tachycardia regardless of location. The 
technique could prevent many patients from being 
Standard VM 
(n=214)
Modified VM 
(n=214)
Increased heart rate 4 3
Hypotension or light-headedness 3 3
Nausea 2 3
Electrocardiograph captured events 0 5
Other* 0 4
Musculoskeletal pain† 0 3
Some participants reported more than one adverse event. 30 non-serious adverse 
events were reported in 21 participants. VM=Valsalva manoeuvre. *Transient 
headache (n=2), shortness of breath (n=1), and cyanosis (n=1) in different 
patients. †Transient chest wall pain on straining (n=3).
Table 3: Adverse events
Standard VM 
(n=214)
Modified VM 
(n=214)
Eligible SVT
Re-entrant, atrial tachycardia, other 184 (86%) 184 (86%)
Undetermined NCT 15 (7%) 12 (6%)
Ineligible rhythms (protocol violations)
Atrial flutter 13 (6%) 12 (6%)
Atrial fibrillation 0 (0%) 2 (1%)
Broad complex tachycardia 1 (<1%) 4 (2%)
Sinus tachycardia 1 (<1%) 0 (0%)
VM=Valsalva manoeuvre. SVT=supraventricular tachycardia. NCT=narrow 
complex tachycardia.
Table 4: Presenting rhythm, as assessed retrospectively by 
electrocardiograph review
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treated with drugs or even seeking health care. Clinicians 
who encounter this condition should consider learning 
the technique and teaching it to patients after a first 
episode of supraventricular tachycardia.
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